Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Vince K. Grolmusz"'
Autor:
Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi, Vince K Grolmusz, Patrick A Cosgrove, Andrea H Bild
Publikováno v:
eLife, Vol 12 (2023)
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inh
Externí odkaz:
https://doaj.org/article/c96b28ace81548d2be96b829718494be
Autor:
Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi, Vince K Grolmusz, Patrick A Cosgrove, Andrea H Bild
SummaryThe mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer. However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3e42c8c902278419a565d8e83de4ba5
https://doi.org/10.1101/2022.12.27.522019
https://doi.org/10.1101/2022.12.27.522019
Autor:
Eleni Farmaki, Rena Emond, Aritro Nath, Vince K. Grolmusz, Patrick A. Cosgrove, Andrea H. Bild
Publikováno v:
Cancer Research. 83:388-388
The mTOR inhibitor everolimus has become an important component for clinical management of metastatic ER+ breast cancer. Despite the improved patient outcomes, progression and resistance will still develop. Therefore, it is important to research stra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d61a051fa3330d4cdb2e77a7afcf54fc
https://doi.org/10.1158/1538-7445.am2023-388
https://doi.org/10.1158/1538-7445.am2023-388